Discontinuation Rate of Antihypertensive Drugs in the Comparative Trials
| Trial | Antihypertensive Drug Class (%) | |||||
|---|---|---|---|---|---|---|
| ACEI | ARB | ACEI + ARB | BB | CCB | DIU | |
| ONTARGET (n = 25,620) | 25 | 23 | 29 | |||
| LIFE (n = 9193) | 23 | 27 | ||||
| VALUE (n = 15,245) | 26 | 24 | ||||
| ALLHAT (n = 24,309) | 27 | 20 | 20 | |||
| UKPDS (n = 758) | 22 | 35 | ||||
| JMIC-B (n = 1650) | 9 | 5 | ||||
ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; DIU, diuretic; BB, β-blocker; ONTARGET, Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial; LIFE, Losartan Intervention For Endpoint Reduction in Hypertension Study; VALUE, Valsartan Antihypertensive Long-Term Use Evaluation; ALLHAT, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial; UKPDS, United Kingdom Prospective Diabetes Study Group; JMIC-B, Japan Multicenter Investigation for Cardiovascular Diseases-B randomized trial.